{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-003966","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-08-10T10:16:08+00:00","discovered_at":"2026-08-10T10:20:00.423992+00:00","generated_at":"2026-08-10T10:20:10.595911+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Silexion starts SIL204 Phase 2/3 in pancreatic cancer; FDA pre-IND expected Q1 2027","bullets":["Phase 2/3 safety run-in for SIL204 in LAPC initiated July 2026; approved by Israel MoH and Germany BfArM.","Early human data expected Q4 2026; IND application and US/EU expansion planned Q1 2027.","SIL204 targets >74% of KRAS mutations in PDAC; sub-nanomolar IC50 across G12D/V/C/R and others.","Preclinical data show tumor growth inhibition, synergy with FOLFIRI, and 11-fold safety margins.","Toxicology package for marketing approval planned H2 2026; collaboration with Catalent and Axolabs for GMP supply."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-003966","json":"https://secwatch.observer/filing/0001178913-26-003966.json","markdown":"https://secwatch.observer/filing/0001178913-26-003966.md","text":"https://secwatch.observer/filing/0001178913-26-003966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003966/0001178913-26-003966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003966/zk2635901.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T10:20:10.595911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}